Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 9,969,000 | 8,454,000 | 8,163,000 | 6,540,000 | 6,825,000 |
| Depreciation Amortization | 3,577,000 | N/A | N/A | N/A | N/A |
| Income taxes - deferred | 1,733,000 | N/A | N/A | N/A | N/A |
| Accounts receivable | 26,000 | -934,000 | -431,000 | -204,000 | -543,000 |
| Accounts payable and accrued liabilities | 490,000 | 512,000 | 246,000 | 323,000 | 245,000 |
| Other Working Capital | -854,000 | -935,000 | -2,569,000 | -2,116,000 | -1,990,000 |
| Other Operating Activity | -874,000 | 5,094,000 | 4,360,000 | 4,667,000 | 3,767,000 |
| Operating Cash Flow | $14,067,000 | $12,191,000 | $9,769,000 | $9,210,000 | $8,304,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 12,631,000 | -10,468,000 | 3,282,000 | -3,331,000 | 376,000 |
| PPE Investments | -1,642,000 | -1,839,000 | -2,048,000 | -2,415,000 | -1,696,000 |
| Net Acquisitions | -26,666,000 | -925,000 | -1,079,000 | -52,000 | -4,522,000 |
| Purchase Of Investment | -124,000 | -296,000 | -10,578,000 | -295,000 | -259,000 |
| Sale Of Investment | 66,000 | 124,000 | 99,000 | 352,000 | 82,000 |
| Purchase Sale Intangibles | -9,000 | -795,000 | -41,000 | -477,000 | -338,000 |
| Other Investing Activity | -21,000 | -815,000 | -43,000 | -503,000 | -338,000 |
| Investing Cash Flow | $-15,756,000 | $-14,219,000 | $-10,367,000 | $-6,244,000 | $-6,357,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,610,000 | -491,000 | -118,000 | -2,111,000 | -3,227,000 |
| Debt Issued | 5,674,000 | 7,052,000 | 1,481,000 | 11,000 | 540,000 |
| Debt Repayment | -5,000 | -22,000 | -68,000 | -59,000 | -182,000 |
| Common Stock Issued | 730,000 | 724,000 | 2,875,000 | 1,849,000 | 653,000 |
| Common Stock Repurchased | -343,000 | -461,000 | -3,348,000 | -6,448,000 | -399,000 |
| Dividend Paid | -4,550,000 | -3,993,000 | -3,395,000 | -2,638,000 | -2,084,000 |
| Other Financing Activity | 0 | 0 | 0 | 78,000 | -232,000 |
| Financing Cash Flow | $4,116,000 | $2,809,000 | $-2,573,000 | $-9,318,000 | $-4,931,000 |
| Exchange Rate Effect | -2,000 | 75,000 | -46,000 | 298,000 | 25,000 |
| Beginning Cash Position | 2,894,000 | 2,038,000 | 5,360,000 | 3,815,000 | 6,321,000 |
| End Cash Position | 5,319,000 | 2,894,000 | 2,038,000 | 5,360,000 | 3,815,000 |
| Net Cash Flow | $2,425,000 | $856,000 | $-3,322,000 | $1,545,000 | $-2,506,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 14,067,000 | 12,191,000 | 9,769,000 | 9,210,000 | 8,304,000 |
| Capital Expenditure | -1,678,000 | -1,887,000 | -2,106,000 | -2,549,000 | -1,779,000 |
| Free Cash Flow | 12,389,000 | 10,304,000 | 7,663,000 | 6,661,000 | 6,525,000 |